ArticleRheumatology advances in practice2025
Enteropathic arthritis is associated with an increased risk of major adverse cardiovascular events and venous thromboembolism.
Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To assess the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in patients with enteropathic arthritis (EA) compared with matched controls. Methods: We performed a 1:1 propensity score matched retrospective cohort study using electronic health records. EA was defined using International Classification of Diseases, 10th Revision code M07 and codes for Crohn's disease or ulcerative colitis, excluding other inflammatory arthritis. Controls had no coded diagnosis of Crohn's disease, ulcerative colitis or inflammatory arthritis. Primary outcomes were MACE and VTE; secondary outcomes included myocardial infarction (MI), stroke, CVD (composite of ischaemic heart disease and cerebrovascular disease), pulmonary embolism (PE) and deep vein thrombosis (DVT). Cohorts were matched for demographics, comorbidities and medications, with analysis using Cox proportional hazards models. Results: We included 5239 matched pairs (mean age 43 years, 63% female), with follow-up of 19 256 person-years (PY) for EA and 42 064 PY for controls. MACE [261 events; incidence rate (IR) 13.6/1000 PY (95% CI 11.9, 15.2)] occurred more frequently in EA compared with controls [407 events; IR 9.7/1000 PY (95% CI 8.7, 10.6)]. Similarly, VTE occurred more frequently in the EA group, with 264 [IR 13.7/1000 PY (95% CI 12.1, 15.4)] compared with 250 events [IR 5.9/1000 PY (95% CI 5.2, 6.7)]. The hazards of MACE [HR 1.40 (95% CI 1.19, 1.66)] and VTE [HR 1.89 (95% CI 1.57, 2.27)] were significantly increased. Results were concordant across CVD, MI and PE, but lacked precision for stroke and DVT. Conclusion: EA is associated with an increased risk of MACE, VTE, MI, CVD and PE. Risk-reduction strategies and lifestyle measures should be clinical and research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.